OHB's IRIS² Role Sharpens Into Focus as Investors Weigh a Record Backlog Against a Distant High
Published on 08/17/2026 at 13:11 | Redaktion boerse-global.de
The scale of Europe's flagship secure-communications constellation is finally taking concrete shape for OHB SE, and the market has responded with a cautious nod of approval. A weekend report in the Handelsblatt identifying the Bremen-based space and defence group as the manufacturer of 18 medium-Earth-orbit (MEO) satellites for the IRIS² programme sent the shares up 6.0 percent on Monday, with the stock changing hands at €272.50.
That advance, however, still leaves the equity roughly 6.2 percent below its 50-day moving average of €290.37 — a telling gap that underscores just how far the shares have retreated from the euphoric levels of earlier this year. At its May peak, the stock touched a 52-week high of €688.00, meaning the current price represents a drawdown of more than 60 percent from that summit, even after a seven-session run that has added 10 percent.
The €15.6 Billion Prize
The IRIS² contract itself is the headline number. The European Commission and the SpaceRISE consortium — comprising SES, Eutelsat and Hispasat — have concluded negotiations for the constellation, with an implementation agreement signed on 7 August. The overall programme encompasses 348 satellites with a total contract value of roughly €15.6 billion, and OHB's role as a core subcontractor involves participation in the development of 330 low-Earth-orbit (LEO) spacecraft alongside the 18 larger, costlier MEO units.
The MEO component is particularly significant for OHB's margin profile, given that these satellites are substantially bigger and more expensive than their LEO counterparts. Parallel reporting has also flagged that Aerospacelab is in line for a contract with a minimum value of €1.8 billion within the same project, with OHB also on board. For investors, the development converts what had previously been a consortium-level association into a defined industrial role.
A Backlog That Keeps Growing
The IRIS² news lands on top of an operating performance that has been quietly building momentum. First-half 2026 results, published on 30 July, showed total output rising 11.4 percent to €627.9 million, while adjusted EBITDA climbed 31.4 percent to €60.4 million. The order book swelled to €3,304 million after six months, up from €3,067 million in the comparable period a year earlier.
Should investors sell immediately? Or is it worth buying OHB SE?
Management has held firm on its full-year guidance: total output of €1,400 million and an adjusted EBITDA margin in the 10.5 to 11.0 percent band. Beyond that, the company's medium-term ambitions call for total output exceeding €4.0 billion at a 13 percent margin — targets that the IRIS² win lends considerably more credibility.
The pipeline has been reinforced by a string of additional contract wins. OHB Italia secured a mandate for the PRISMA Second Generation mission for the Italian space agency ASI, a programme running through to the end of 2031. More notably, the group booked a €248 million order for EPS-Sterna, a 20-satellite micro-constellation that stands as the largest single contract in the company's history.
Funding the Ambition
None of this growth comes cheap. OHB raised €484 million through a capital increase in June, a move that bolsters the balance sheet but also dilutes existing holders. The company has simultaneously been widening its strategic footprint: a partnership with Rheinmetall for the SATCOMBw 4 programme, and the creation of the KIRK joint venture alongside Helsing, Hensoldt and Kongsberg Defence & Aerospace.
A Cautionary Note From the Top
The bullish narrative is not without its caveats. In an investor call, chief executive Marco Fuchs warned that Europe risks falling behind SpaceX in the launch-capability race unless governments commit fresh funding to the spaceport at Kourou. Without additional investment in Ariane 6 launch capacity, the continent's ability to deploy and maintain constellations like IRIS² could be compromised — a structural constraint that no single contract award can resolve.
The Valuation Question
Analysts who initiated coverage in early August set price targets ranging from €250 to €360, and the IRIS² confirmation gives them fresh material to revisit those figures. The market's muted reaction to the final contract signing — the stock closed Friday at €257.00, down 1.0 percent on the day — suggests much of the good news had already been priced in during the rally that has more than doubled the shares since the start of the year.
The shares are also approaching a moment of institutional significance: the Deutsche Börse's next index review in September, when OHB will seek qualification for the TecDAX. Whether the stock can reclaim its short-term trend level and close the gap to those analyst targets may depend less on contract announcements and more on how quickly the IRIS² backlog translates into visible revenue and margin contribution — and whether the current valuation already reflects the substance that the order book now clearly contains.
Ad
OHB SE Stock: New Analysis - 17 August
Fresh OHB SE information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
